PROVO, Utah--(BUSINESS WIRE)--Raser Technologies, Inc. (NYSE: RZ), an energy technology company, announced today that it will present at Projects & Money 2010 in New Orleans and Geothermal Energy Finance Forum in New York City.
| What: | Projects & Money 2010 | |
| Where: | Hilton New Orleans Riverside, New Orleans, La. | |
| When: | January 13, 2010 | |
| Time: | 11:45 a.m.-12:30 p.m. local time | |
| What: | Geothermal Energy Finance Forum | |
| Where: | The Ritz-Carlton, Battery Park, New York, N.Y. | |
| When: | January 14, 2010 | |
| Time: | 9:00-10:30 a.m. local time |
About Raser Technologies
Raser (NYSE: RZ) is an environmental energy technology company focused on geothermal power development and technology licensing. Raser’s Power Systems segment is seeking to develop clean, renewable geothermal electric power plants and bottom-cycling operations, incorporating licensed heat transfer technology. Raser’s Transportation and Industrial segment focuses on extended-range plug-in-hybrid vehicle solutions and using Raser’s award-winning Symetron™ technology to improve the torque density and efficiency of the electric motors and drive systems used in electric and hybrid-electric vehicle powertrains and industrial applications. Further information on Raser may be found at: www.rasertech.com.
NicOx S.A. (NYSE Euronext Paris: COX) today announced that a Marketing Authorization Application (MAA) for naproxcinod has been submitted to the European Medicines Agency (EMEA) through the centralized procedure, seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). This follows the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) in September that has recently been accepted for filing.
Naproxcinod is NicOx's lead investigational compound and the first in a new class of anti-inflammatory agents known as CINODs (Cyclooxygenase-Inhibiting Nitric Oxide Donators). The MAA file is supported by data from a large program of 34 clinical trials that involved more than 4,000 subjects treated with naproxcinod. The program evaluated the efficacy of naproxcinod in relieving signs and symptoms of osteoarthritis, as well as its safety, with a particular care given to its effect on blood pressure.
Continue at http://www.marketwire.com/press-release/Nicox-Paris-COX-1094377.html
Advanced Technology Investment Company LLC (ATIC) of Abu Dhabi and Chartered Semiconductor Manufacturing Ltd. (Chartered) of Singapore announced that ATIC’s acquisition of Chartered becomes effective today.
ATIC made its acquisition by way of a scheme of arrangement under section 210 of the Companies Act of Singapore (the Scheme), and Chartered ordinary shareholders approved the acquisition last month. As all the requisite regulatory approvals and conditions precedent have been received, a copy of the order of the High Court sanctioning the Scheme was lodged with the Accounting and Corporate Regulatory Authority of Singapore today, making the Scheme effective and binding on all Chartered ordinary shareholders.
http://www.businesswire.com/portal/site/home/permalink/?ndmViewId=news_view&newsId=20091217006454&newsLang=en
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today provided an update on new clinical developments and other initiatives related to Ceplene® (histamine dihydrochloride), the Company’s therapy approved in the European Union for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first remission.
EpiCept announced plans to initiate two new studies for Ceplene and provided an update on another study for Ceplene intended to help achieve an expanded indication and broaden use for the drug.
Read full story at
http://www.businesswire.com/portal/site/home/permalink/?ndmViewId=news_view&newsId=20091214006392&newsLang=en
COLLEGE PARK, Md., Dec. 9 /PRNewswire-USNewswire/ -- A WorldPublicOpinion.org poll finds that publics in 14 of 21 nations around the world think their governments should be more ready to cooperate with others to achieve mutual gains.
The poll comes at a time when international cooperation figures prominently in the news, as world leaders gather in Copenhagen to discuss climate change and Europe adopts the new Lisbon Treaty. Even President Obama's Nobel Peace Prize is due largely to his cooperative overtures. Indeed, the poll finds that 15 of 19 nations now see the United States as being generally cooperative.
Continue at
http://www.prnewswire.com/news-releases/poll-finds-most-publics-around-the-world-want-their-governments-to-be-more-cooperative-78897407.html
